-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓EURISIN JP3942400007-
Astellas PharmaBörse Börse DüsseldorfEURSymbol YPH
-
Astellas PharmaBörse Börse MünchenEURSymbol YPH
-
ASTELLAS PHARMA INCBörse Quotrix System der Börse DüsseldorfEURSymbol YPH
-
ASTELLAS PHARMA INCBörse Gettex System der Börse MünchenEURSymbol YPH
-
ASTELLAS PHARMA INCBörse Tradegate System der Deutsche Börse AG (60%)EURSymbol YPH
-
ASTELLAS PHARMA INCBörse Börse StuttgartEURSymbol YPH
-
Astellas PharmaBörse Amerikanscher Freiverkehr OTC oder "Pink Sheets"ISIN JP3942400007USDSymbol 4503
-
USDAstellas PharmaBörse Amerikanscher Freiverkehr OTC oder "Pink Sheets"
-
ISIN JP3942400007 WKN: 856273EURSymbol YPH
-
JPYISIN JP3942400007
-
USD
-
JPY
-
EUR
-
Astellas Pharma Inc.Börse Freiverkehr OTC
-
ISIN JP3942400007
WKN 856273
Symbol YPH
Währung
EUR
Marktkapitalisierung
14.283.000.000
Mitarbeiter
14.522
Zahlte zuletzt am 30.03.2021 eine Dividende von 21 JPY . Seit damals wurde keine Dividende mehr ausgeschüttet Übersicht
Die Dividendenrendite
entsprach 109.038,37 % p. a.
beim aktuellen Kurs von 13,01 EUR +1,16%
Portrait der Astellas Pharma Aktie
Das Unternehmen Astellas Pharma aus Japan beschäftigt 14.522 Mitarbeiter und ist in den Bereichen Chemie & Pharma, Pharma tätig.
Astellas Pharma ist in mehr als 54 ETFs enthalten und somit ein eher allgemein bekannter Wert. Der Spitzenreiter UBS ETF (LU) MSCI Japan Socially Responsible UCITS ETF (hedged to EUR) A-acc gewichtet Astellas Pharma mit 3,82% im ETF.
Entdecke die 6 ETFs in denen Astellas Pharma am höchsten gewichtet ist Insgesamt in 54 ETFs enthalten
Dir gefallen die Informationen zu Astellas Pharma?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
Dir gefallen die Informationen zu Astellas Pharma?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
Dir gefallen die Informationen zu Astellas Pharma?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
Dir gefallen die Informationen zu Astellas Pharma?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
30 News & Informationen zur Astellas Pharma Aktie
Global Antidiabetic Drug Market Report 2021-2026 – Opportunities in New Innovations
/PRNewswire/ — The “Global Antidiabetic Drug Market (2021-2026) by Drug Type, Diabetic Type, Patient, Geography, Competitive Analysis and the Impact of…
PureTech Health plc : – Half-Year Report
Strong capital base and cash runway expected into the first quarter of 2025, with PureTech level cash and cash equivalents of $409.7 million1 and consolidated cash and cash equivalents of $439.8… | August 24, 2021
Astellas Partners with LabCentral to Help Emerging Biotechs Accelerate Preclinical Scientific Research
/PRNewswire/ — Astellas Venture Management LLC (President: Kazunori Maruyama, Ph.D., “AVM”), a wholly-owned venture capital subsidiary of Astellas Pharma…
Global Antifungals Market Report 2021: Market is Expected to Reach $13.71 Billion in 2025 – Long-term Forecast to 2030
DUBLIN, Aug. 13, 2021 /PRNewswire/ — The 'Antifungals Global Market Report 2021: COVID-19 Impact and Recovery to 2030' report has been added to R…
Global Antifungals Market Report 2021: Market is Expected to Reach $13.71 Billion in 2025 – Long-term Forecast to 2030
/PRNewswire/ — The
Regenerative Medicine Market Size Worth $57.08 Billion By 2027: Grand View Research, Inc.
SAN FRANCISCO, Aug. 12, 2021 /PRNewswire/ — The global regenerative medicine market size is expected to reach USD 57.08 billion by 2027, growing …
AstraZeneca : Update on US regulatory review of roxadustat in anaemia of chronic kidney disease (Form 6-K)
Update on US regulatory review of roxadustat
in anaemia of chronic kidney disease
The US Food and Drug Administration has issued a complete response letter … | August 11, 2021
AstraZeneca : Update on US regulatory review of roxadustat in anaemia of chronic kidney disease
The US Food and Drug Administration has issued a complete response letter regarding the New Drug Application for roxadustat for the treatment of anaemia of chronic kidney disease ,… | August 11, 2021
Global $191 Billion Orphan Drugs Markets To 2026: Therapeutic Applications In Rare And Orphan Diseases, Regulatory Framework, Patents, And Innovations
DUBLIN, Aug. 5, 2021 /PRNewswire/ — The
Global Cancer Therapies Market to Reach $204.2 Billion by 2024
/PRNewswire/ — A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled…
Astellas Pharma, Inc. (ALPMF) Q1 2022 Results – Earnings Call Transcript
Astellas Pharma, Inc. (OTCPK:ALPMF) Q1 2022 Results Conference Call July 30, 2021 03:00 AM ET Company Participants Naoki Okamura – CSO & CFO Mike Kitagawa – Senior VP of Development…
Astellas Pharma Inc. 2021 Q2 – Results – Earnings Call Presentation (OTCMKTS:ALPMF)
The following slide deck was published by Astellas Pharma Inc.
Global Preventive Vaccines Market is estimated to be US$ 69 billion by 2030 with a CAGR of 6.0% during the forecast period – by PMI
Covina, CA, July 22, 2021 (GLOBE NEWSWIRE) — The Global Preventive Vaccine market accounted for US$ 39.45 Billion in 2020 and is estimated to be US$…
Global Preventive Vaccines Market is estimated to be US$ 69 billion by 2030 with a CAGR of 6.0% during the forecast period – by PMI
Covina, CA, July 22, 2021 (GLOBE NEWSWIRE) — The Global Preventive Vaccine market accounted for US$ 39.45 Billion in 2020 and is estimated to be US$…
Warburg Pincus-Backed AI Drug Firm Insilico Weighs U.S. IPO
(Bloomberg) — Insilico Medicine, a company that uses artificial intelligence to drive drug discovery, is considering a U.S. initial public offering that could raise about $300 million, according to people familiar with the matter.
Global Castrate Resistant Prostate Cancer (CRPC) Market to Surpass US$ 16.4 Billion by 2028, Says Coherent Market Insights (CMI)
SEATTLE, July 20, 2021 (GLOBE NEWSWIRE) — According to Coherent Market Insights, the global castrate-resistant prostate cancer market is estimated to be…
Astellas Pharma : U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer
– Regular Approval Based on Overall Survival Results from Confirmatory EV-301 Trial –
– First and Only FDA-Approved Therapy for Urothelial Cancer Patients Who Are Cisplatin-Ineligible and Have… | July 9, 2021
PADCEV (enfortumab Vedotin-ejfv) 20 Mg Vial US (Photo: Business Wire)
Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the U.S. Food and Drug
Global $79.2 Billion Kinase Inhibitors Markets to 2026: Antineoplastic Agents, Age-related Macular Degeneration (AMD), Immunosuppressant
/PRNewswire/ — The
Global $79.2 Billion Kinase Inhibitors Markets To 2026: Antineoplastic Agents, Age-related Macular Degeneration (AMD), Immunosuppressant
DUBLIN, July 2, 2021 /PRNewswire/ — The
Antibiotics Market Size Worth USD 64,532 Million by 2025 at 4.8% CAGR – Report by Market Research Future (MRFR)
Antibiotics Market Insights and Industry Analysis by Spectrum of Activity (Broad-spectrum Antibiotic, Narrow-spectrum Antibiotic), Drug Class…
Actinium Pharmaceuticals Announces Inclusion In Russell Microcap® Index
NEW YORK, June 28, 2021 /PRNewswire/ — Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”) today announced today that it will
The Worldwide Cryptococcosis Treatment Industry is Expected to Reach $6 Billion by 2026 at a CAGR of 4.5% from 2021
/PRNewswire/ — The “Global Cryptococcosis Treatment Market (2021-2026) byTreatment, Distribution Channel, Geography and the Impact of COVID-19 with Ansoff…
The Worldwide Cryptococcosis Treatment Industry is Expected to Reach $6 Billion by 2026 at a CAGR of 4.5% from 2021
/PRNewswire/ — The “Global Cryptococcosis Treatment Market (2021-2026) byTreatment, Distribution Channel, Geography and the Impact of COVID-19 with Ansoff…
United Immunity and Xyphos, an Astellas Company, to Collaborate on Next Generation Nano-Immunotherapies for Cancer Treatment
TOKYO, Jan. 15, 2021 /PRNewswire/ — United Immunity, Co., Ltd. (CEO, Naozumi Harada, Ph.D. Mie, Japan), a drug discovery biotech specializing in …
Actinium And Astellas Announce Research Collaboration Focused On Novel Actinium-225 Based Targeted Radiotherapies
NEW YORK, Jan. 13, 2021 /PRNewswire/ — Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium”) today announced the research collaboration with
Venture Capital Access Online
Global Stem Cell Therapy Market Report 2020: Market to Recover and Reach $14.76 Billion in 2023 at a CAGR of 19.62% – Forecast to 2030
Dublin, Jan. 05, 2021 (GLOBE NEWSWIRE) — The “Stem Cell Therapy Global Market Report 2020-30: COVID-19 Growth and Change” report has been added to …
Global Paediatric Vaccine Market Report 2020: Market is Estimated to be $45 Bn in 2020 and is Expected to Reach $74.5 Bn by 2025
Dublin, Jan. 05, 2021 (GLOBE NEWSWIRE) — The “Global Paediatric Vaccine market (2020-2025) by Type, Technology, Application, Geography and the Impact …
Amyotrophic Lateral Sclerosis Market Insight, Epidemiology and Market Forecast Report 2017-2030: Focus on United States, Germany, Spain, Italy, France, United Kingdom and Japan
Dublin, Jan. 05, 2021 (GLOBE NEWSWIRE) — The “Amyotrophic Lateral Sclerosis Market Insight, Epidemiology and Market Forecast -2030” drug pipelines …